Other
Journal
News Categories
- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
- Guidelines
Binosto (Alendronate Sodium) Available in U.S. for Treatment of Osteoporosis
Effervescent tablets dissolve in water to form buffered solution (Oct. 11)
Mission Pharmacal Company, based in San Antonio, Tex., announced on October 11 that Binosto (alendronate sodium) effervescent tablets for buffered oral solution (70 mg) are now available by prescription in the U.S. The FDA approved Binosto in March 2012 for the treatment of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. Binosto delivers alendronate sodium in a once-weekly, buffered solution, which should benefit patients who prefer not to swallow tablets, suffer with dysphagia, or have other medical difficulties swallowing pills.Although osteoporosis is often thought of as a disease that affects mostly women, the disorder also occurs in men. While women experience relatively rapid bone loss in the first few years after menopause, by about age 65, men and women lose bone mass at the same rate. Osteoporosis affects more than 200 million women and men worldwide and more than 10 million people in the U.S.
Binosto is a once-weekly, strawberry-flavored effervescent tablet containing alendronate sodium (70 mg) that rapidly dissolves in half a glass (4 oz) of room-temperature water to make a buffered solution. The product is available in packs of four.
For more information, visit the Mission Pharmacal Company Web site.
Mission Pharmacal Company
